MAPT and Alzheimer disease: However, we believe our study remains the first to evaluate subcortical structural shapes in EOAD and LOAD patients, using the three major imaging biomarkers tau PET, amyloid PET, and MRI which can provide valuable evidence of in vivo findings in AD.